News

News & Reports 2018-03-22T10:04:39+00:00

Have some news you want to share with the Oregon Bio community?  Fill out our submission form.

SAN DIEGO BIO EXECUTIVE NAMED OREGON BIOSCIENCE ASSOCIATION’S NEW EXECUTIVE DIRECTOR

Bozinovic comes from Biocom Institute to join the local bio organization as it turns 30

(Portland, Ore.) –The Oregon Bioscience Association’s Board of Directors announced today the selection of its new Executive Director, Liisa Bozinovic, who will assume leadership of the trade/industry association on April 11, 2019.

Bozinovic comes to Oregon’s growing life science and medical device industry organization from its peer organization, Biocom, where she currently […]

March 19th, 2019|

Oregon biotech company raises $5M to fuel growth from lab to clinic

By  – Staff Reporter, Portland Business Journal

Eugene-based NemaMetrix, a biotech company that developed DNA testing equipment using nematode worms, has raised another $5 million, according to a filing with the U.S. Securities and Exchange Commission.

Oregon Venture Fund was the lead investor and Rogue Venture Partners also participated, […]

March 11th, 2019|

AbSci Establishes New Collaboration with Sanofi

AbSci and Sanofi entered into a collaboration to improve the manufacturability for two of Sanofi’s biotherapeutics
VANCOUVER, Wash., Jan. 9, 2019 /PRNewswire/

AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi. Under the terms of the agreement, AbSci will apply its breakthrough E.coli manufacturing platform, SoluProTM, and its novel optimization assay system, to two of Sanofi’s biotherapeutic molecules. AbSci’s proprietary technology platform is designed with the ability […]

January 18th, 2019|

Veana Therapeutics secures NIH funding for VIMO

Veana Therapeutics is pleased to announce a Phase I Small Business Innovation Research (SBIR) grant award from the NIH National Cancer Institute to conduct proof-of-concept pre-clinical studies of its lead product, VIMO (Veana Immune Modulator) in combination with immune checkpoint inhibitors in triple negative breast cancer. Learn more about Veana here.

November 12th, 2018|

DesignMedix Inc. wins PBJ’s Manufacturer of the Year (1-10 employees)

By Denise Szott – Contributing writer for Portland Business Journal

The Portland company developed a drug to cure malaria that is easy and cheap to manufacture

DesignMedix co-founder and Chief Scientific Officer David Peyton and a student carry out research at the DesignMedix Lab in the Portland State

 

Most of us have felt annoyed […]

November 12th, 2018|

Medintellibase150shaded

As with cancer and HIV infections, progress in treatment for the genetic disorder cystic fibrosis has come with ever-more sophisticated cocktails of drugs. Proteostasis Therapeutics (NASDAQ: PTI) is o [...]

Troubled Allergan is taking steps to appease investors, including bringing in a big-name biotech executive for guidance. But if the company thought those moves would be enough to placate angry activis [...]

Liquid biopsy developer Epic Sciences has brought on Myriad Genetics' oncology chief, Lloyd Sanders, to be its new president and CEO. [...]

Just weeks after kick-starting its phase 1 test, Arch Oncology has gathered $50 million in financing to help see its immuno-oncology asset through the clinic. [...]

FierceMadness' Round 2 battle of pharma ad campaigns saw tourney outs for Verzenio, Chantix and Orilissa in the cut to 16 contenders, while work for brands Repatha, Keytruda and Allergan continue [...]

Swedish p53 cancer biotech Aprea Therapeutics has nabbed former Agios senior medical director Eyal Attar as its senior vice president and chief medical officer. [...]

French biotech AlzProtect has teamed up with CRO Parexel for its midstage test of AZP2006 in patients with progressive supranuclear palsy. [...]

NEW ORLEANS (AP) -- The pharmaceutical companies behind the widely advertised blood thinner Xarelto reached a $775 million settlement in 25,000 lawsuits alleging patients were not adequately warned ab [...]